CoChat

EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions

Marleau, Sylvie, Harb, Diala, Bujold, Kim, Avallone, Roberta, Iken, Khadija, Wang, Yanfei, Demers, Annie, Sirois, Martin G., Febbraio, Maria, Silverstein, Roy L., Tremblay, André, Ong, Huy · 2005 · The FASEB Journal
Cited by 115

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

CD36, a type B scavenger receptor expressed on macrophages, appears to play a major role in fatty streak formation through scavenging oxidatively modified lipoproteins in the arterial wall. We tested the hypothesis that EP 80317, a novel CD36 ligand derived from the growth hormone (GH)‐releasing peptide family but devoided of any GH releasing activity, exerts anti‐atherosclerotic effects in apolipoprotein E‐deficient (apoE −/− ) mice fed an atherogenic diet from 6 wk of age. Daily subcutaneous injections of EP 80317 (300 µg/kg) or vehicle were initiated at 6, 10, 12, or 14 wk until death at 18 wk. En face analyses of the entire aortic tree revealed a striking reduction (up to 51%) of lesion areas in EP 80317‐treated apoE −/− mice compared with controls. Chronic treatment with EP 80317 (12 wk) is also associated with a 30% decrease in total plasma cholesterol, suggesting potential effects of this drug on cholesterol metabolism at the intestine/hepatic levels. EP 80317 exerts both preventive and curative effects on atherosclerotic lesion progression that were shown to be reversible after cessation of treatment. At the macrophage level, EP 80317 reduced oxidized low density lipoproteins internalization and up‐regulated genes involved in cholesterol efflux, including peroxisome proliferator‐activated receptor γ (PPARγ), liver x receptor α (LXRα), and the ATP binding cassette (ABC) transporters ABCA1 and ABCG1, supporting a role in regulating peripheral cholesterol trafficking. Importantly, the effects of EP 80317 were shown to be CD36 dependent, inasmuch as no anti‐atherosclerotic or hypocholesterolemic effects were observed in apoE/CD36 double‐deficient mice. In addition, long‐term treatment of apoE/CD36 double‐deficient mice with EP 80317 did not modulate the expression of genes of the PPARγ‐LXRα‐ABC transporters pathway. Our results suggest that EP 80317, as a CD36 ligand, might be a prototype for a novel class of anti‐atherosclerotic agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.04-3253fje

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 115

Metadata

Authors
Marleau, S., Harb, D., Bujold, K., Avallone, R., Iken, K., Wang, Y., Demers, A., Sirois, M. G., Febbraio, M., Silverstein, R. L., Tremblay, A., & Ong, H.
Venue
The FASEB Journal
Publisher
Wiley
Published
2005-08-25
Volume
19
Issue
13
Pages
1869-1871
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2154013127
Cited by
115
References
5
FWCI
6.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions. https://app.cochat.ai/papers/10.1096/fj.04-3253fje
The paper
Marleau, S., Harb, D., Bujold, K., Avallone, R., Iken, K., Wang, Y., Demers, A., Sirois, M. G., Febbraio, M., Silverstein, R. L., Tremblay, A., & Ong, H. (2005). EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions. The FASEB Journal. https://doi.org/10.1096/fj.04-3253fje

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.